BREA, Calif., May 1, 2018 /PRNewswire/ -- Beckman Coulter
announced today the release of the DxH 900 hematology analyzer,
giving mid- to high-volume clinical laboratories the ability to
perform complete blood count and white blood cell differential
tests with minimal repeats. The DxH 900 is now available for sale
in Europe, the United States, Canada, Australia and New
Zealand. The DxH 900 analyzer offers advanced technologies
to support patient care, by delivering the right results the first
time. Foundational to the system are its core technologies,
including the enhanced Coulter Principle, VCS 360 and DataFusion.
These features offer high-resolution analysis of cells in their
near-native states, providing a precise cellular assessment for
excellent red blood cell, platelet and white blood cell test
results on the first pass.
"The DxH 900 hematology analyzer is an example of our commitment
to the voice of the customer. We had over 100 of our customers view
prototypes, and we enhanced our designs based on their input.
Truly, the DxH 900 was designed by customers for customers," said
Peter Soltani, Ph.D., senior vice
president and general manager of the hematology business at Beckman
Coulter. "The suite of technologies is intended to help
laboratories deliver quality results for fast, accurate clinical
decision-making. At the same time, the system includes automated
solutions that streamline the number of procedural steps needed to
produce those results, offering predictable performance and greater
laboratory efficiency."
The DxH 900 analyzer demonstrates industry-leading 93%
first-pass throughput,1 providing accurate flagging and
reducing the number of slide reviews. This helps to generate
reportable results as quickly as possible, reducing the time,
supplies and costs that may be required for systems with higher
repeat rates. Adding to this is the analyzer's lean reagent
portfolio, which includes four reagents compared to 11 reagents
required by other analyzers.2 Further, the DxH 900
features one of the smallest footprints in its class, making it
highly efficient in utilization of laboratory space.
Many of the parameters available with the DxH 900 analyzer are
designed to directly impact patient care by addressing critical
conditions, such as thrombocytopenia, anemia and leukopenia.
Sepsis, is another often-deadly condition that affects millions of
people worldwide each year. A recognized global healthcare concern,
sepsis puts patients in grave danger and places a significant
burden on the healthcare system as a whole. Beckman Coulter is
evaluating a hematology sepsis* parameter that is part of a
routinely ordered test in the emergency department, where earlier
recognition and treatment of sepsis can begin. This test can be
performed on the DxH 900 analyzer.
The DxH 900 hematology analyzer complements the recently
announced DxH 520* system, and further expands Beckman Coulter's
hematology portfolio. These solutions provide a high level of
continuity of care for clinical laboratories, regardless of whether
they are small- or high-volume facilities.
About Beckman Coulter
Beckman Coulter Diagnostics helps healthcare and laboratory
professionals provide better patient care by delivering the
accurate diagnostic information they need, when they need it. For
over 80 years, Beckman Coulter has been the partner of choice for
healthcare organizations. Our scalable instruments, comprehensive
diagnostic tests and business management services are trusted by
hospitals, laboratories and other critical care settings around the
world. We share in our customers' mission toward continuous
improvement and quality patient care because we believe when
efficiency and clinical outcomes are improved, patients benefit and
we can move healthcare forward for every person.
1. DxH series side-by-side results
documentation.
2. Automated hematology analyzer manufacturers'
Instructions for Use (IFUs).
Disclaimer: The Early Sepsis Indicator is not
available in all countries.
* CE Marked and is pending 510(k) clearance by
the U.S. FDA. Not yet available for in vitro diagnostic use in the
U.S.
© 2018 Beckman Coulter. All rights reserved. Beckman Coulter,
the stylized logo and the Beckman Coulter product and service marks
mentioned herein are trademarks or registered trademarks of Beckman
Coulter, Inc. in the United States
and other countries.
View original content with
multimedia:http://www.prnewswire.com/news-releases/beckman-coulter-launches-the-dxh-900-hematology-analyzer-300639596.html
SOURCE Beckman Coulter Diagnostics